PUFAs Add Fuel to Crohn's Disease-associated AIEC-induced Enteritis by Exacerbating Intestinal Epithelial Lipid Peroxidation
Overview
Affiliations
Polyunsaturated fatty acids (PUFAs) have been shown to exacerbate Crohn's disease (CD) by promoting lipid peroxidation (LPO) of intestinal epithelial cells (IECs). Dysbiosis of the gut microbiota may play a crucial role in this process. CD patients often exhibit an increased abundance of () in the gut, and the colonization of adherent-invasive (AIEC) is implicated in the initiation of intestinal inflammation in CD. However, the impact of AIEC on LPO remains unclear. In this study, we observed that AIEC colonization in the terminal ileum of CD patients was associated with decreased levels of glutathione peroxidase 4 (GPX4) and ferritin heavy chain (FTH) in the intestinal epithelium, along with elevated levels of 4-Hydroxynonenal (4-HNE). experiments demonstrated that AIEC infection reduced the levels of GPX4 and FTH, increased LPO, and induced ferroptosis in IECs. Furthermore, arachidonic acid (AA) and docosahexaenoic acid (DHA) supplementation in AIEC-infected IECs significantly aggravated LPO and ferroptosis. However, overexpression of GPX4 rescued AIEC-induced LPO and ferroptosis in IECs. Our results further confirmed that AIEC with AA supplementation, associated with excessive LPO and cell death in IECs, worsened colitis in the DSS mouse model and induced enteritis in the antibiotic cocktail pre-treatment mouse model . Moreover, treatment with ferrostatin-1, a ferroptosis inhibitor, alleviated AIEC with AA supplementation-induced enteritis in mice, accompanied by reduced LPO and cell death in IECs. Our findings suggest that AIEC, in combination with PUFA supplementation, can induce and exacerbate intestinal inflammation, primarily through increased LPO and ferroptosis in IECs.
Angiogenesis, a key point in the association of gut microbiota and its metabolites with disease.
Wang Y, Bai M, Peng Q, Li L, Tian F, Guo Y Eur J Med Res. 2024; 29(1):614.
PMID: 39710789 PMC: 11664877. DOI: 10.1186/s40001-024-02224-5.
Ferroptosis: mechanisms and therapeutic targets.
Zhou Q, Meng Y, Le J, Sun Y, Dian Y, Yao L MedComm (2020). 2024; 5(12):e70010.
PMID: 39568772 PMC: 11577302. DOI: 10.1002/mco2.70010.
Xiong J, Yang L, Wang L, Zhi S, Zhao M, Xu C Aquac Nutr. 2024; 2024:7631021.
PMID: 39555544 PMC: 11524719. DOI: 10.1155/2024/7631021.
Chatterjee P, Canale V, King S, Shawki A, Lei H, Haddad M medRxiv. 2024; .
PMID: 39399045 PMC: 11469354. DOI: 10.1101/2024.09.26.24314341.
The evolving process of ferroptosis in thyroid cancer: Novel mechanisms and opportunities.
Yin L, Luo X, Zhang X, Cheng B J Cell Mol Med. 2024; 28(16):e18587.
PMID: 39163517 PMC: 11335058. DOI: 10.1111/jcmm.18587.